Ian M. Orme
Professor

Phone: 491-5777
Fax: 491-1815
Email: Ian.Orme@colostate.edu
Office: C331 Microbiology Building
Lab: C312 Microbiology Building

 

Degrees

• B.Sc., Kings College, University of London, England
• Ph.D., University of London

Research Interests

Bill and Melinda Gates TB Drug Accelerator Grant - Assay Standardization Website

Immunology and therapy of Tuberculosis

• A continuing objective of my laboratory is to develop relevant small animal models of tuberculosis, the world’s most devastating bacterial disease. Over the past decade we have made major contributions to understanding the basis of the pulmonary immune response to tuberculosis, using diverse technologies ranging from advanced flow cytometry to the use of mice in which specific genes have been selectively disrupted [gene-knockout mice]. In the guinea pig model, an animal that exhibits lung pathology very similar to that seen in humans infected with tuberculosis, we have systematically described the course of the infection using standard histology, immunohistochemistry, and magnetic resonance imaging. Our laboratory is the first to demonstrate the T cell mediated immune response in the lungs, using breakthrough flow cytometry. This information, collectively, is being applied to our vaccine development and drug screening programs. Amongst our recent achievements, we have described a new class of vaccines specifically targeting the Toll-2 receptor, and have described the apparent location of bacteria that persist in the lungs after prolonged drug treatment. These observations are providing the basis for new therapeutic approaches to treat this very serious global disease.

Selected RecentPublications

Pub Med for Orme IM.

• Lenaerts AJ, Lasco T, Cantarero L, Aly S, Ehlers S, Andries K, Orme IM, Basaraba RJ. 2007. Location and susceptibility of persisting mycobacteria in the guinea pig model of tuberculosis. Antimicrob Agents Chemother. 2007 51, 3338-45
• Wang B Henao-Tamayo M Harton M Basaraba RJ Orme IM. 2007. A Toll-like Receptor-2 directed fusion protein vaccine against tuberculosis. Clin Vaccine Immunol. 14, 902-6
• Hinchey J, Lee S, Manjunatha V, Chen B, Basaraba RJ, Jeon BY, Derrick SC, Chan J, Braunstein M, Orme IM, Morris SL, Jacobs WR, Porcelli SA. 2007. Enhanced Priming of Adaptive Immunity by a Proapoptotic Mutant of Mycobacterium tuberculosis. J Clin Invest. 117; 2279-2288.
• Ordway D Palanisamy G Henao-Tamayo M Smith EE Shanley C Orme IM Basaraba RJ. 2007 The cellular immune response to Mycobacterium tuberculosis infection in the guinea pig. J Immunol 179; 2532-41.
• Ordway D Henao-Tamayo M Harton M Palanisamy G Troudt J Basaraba RJ Orme IM. 2007. The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. J Immunol. 179; 522-31.
• Orme IM. Tuberculosis: Immunity. Wiley Electronic Library System. 2007